
Opinion|Videos|May 14, 2024
Applying NCCN Guidelines in the Treatment of mBC
Britny Brown, PharmD, BCOP, discusses the importance of the NCCN guidelines in the treatment of metastatic breast cancer (mBC) and explains how the NCCN recommendations for CDK4/6 inhibitors differ for first-line patients.
Advertisement
Episodes in this series

Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
MONALEESA Data Reveal Robust Long-Term Disease Control With Ribociclib
2
A Supplemental Blood Test to Bridge Gaps in Breast Cancer Screening Access
3
Advancing Treatment After CDK4/6 Inhibitor Progression in HR+/HER2– Breast Cancer
4
AI-Powered Deep Proteomics Enables Early, Non-Imaging Detection of Breast Cancer With MRI-Comparable Accuracy
5




















































































































































































































